Among FDA’s generic drug research priorities for this fiscal year will be ways to review potential abuse-deterrent formulations specifically targeting the nasal route.
It is a particularly timely focus for the agency as it continues pushing for scientific advances in the area and responds to critics about its handling of opioid products with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?